Royalty Pharma Plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (January 2026)

6 slides from Royalty Pharma's investor presentation, January 2026

  1. Slide 1: R&D co-funding for TEV-53408

    R&D co-funding for TEV-53408 January 2026

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o

  3. Slide 3: Expanding Teva partnership with R&D funding on TEV-'408

    3 Expanding Teva partnership with R&D funding on TEV-‘408 1 2 3 TEV-‘408 – potential BIC anti IL-15 Significant unmet patient need in Deal structure provides attractive mAB for autoimmune diseases lead indication vitiligo risk/reward Emerging Phase 1b vitiligo data Chronic skin condition causing are

  4. Slide 4: R&D funding collaboration on key pipeline program

    4 R&D funding collaboration on key pipeline program Deal structure drives attractive risk/reward RP option to scale investment following Phase 2b results Teva provides TEV-‘408 Phase Royalty Pharma and • Up to $500m to co-fund development of TEV-‘408 for vitiligo 2b vitiligo results, decision to Tev

  5. Slide 5: Vitiligo – underserved autoimmune condition with high unmet need

    5 Vitiligo – underserved autoimmune condition with high unmet need Disease background Visible depigmentation from melanocyte destruction • Vitiligo is driven by cytotoxic T-cells causing melanocyte destruction and visible depigmentation • Potentially manifested on the skin (hands, feet, arms, face,

  6. Slide 6: TEV-'408 – potential first- & best-in-class IL-15 for autoimmune diseases

    6 TEV-‘408 – potential first- & best-in-class IL-15 for autoimmune diseases TEV-‘408 an attractive R&D funding candidate Market dynamics in vitiligo ✓ Attractive profile ✓ ~70% Potential for best-in-class Self-administered No approved systemic Of patients in RP survey either efficacy and durability

Royalty Pharma — Investor Presentation (January 2026) on 6ix